Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag spark-therapeutics

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Gene therapies for rare inherited diseases are very expensive, as they tend to be the only therapeutic option available to patients and are often curative.

Gene Therapy

Gene Therapy FDA Approval Gene Genetic Disease

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

XTalks

AUGUST 23, 2021

In particular, it sparked an exploration of whether an anti-amyloid drug could show synergies when administered along with an agent targeting tau, or if the former could be used to essentially render a patient “amyloid-negative” before starting on an anti-tau therapy to potentially increase its efficacy.

Clinical Trials

Clinical Trials Clinical Trials Trials Drugs

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

Stay Connected